These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36879424)
1. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. Schwartz GG; Szarek M; Bhatt DL; Bittner VA; Bujas-Bobanovic M; Diaz R; Fazio S; Fras Z; Goodman SG; Harrington RA; Jukema JW; Manvelian G; Pordy R; Ray KK; Scemama M; White HD; Steg PG; Eur Heart J; 2023 Mar; 44(16):1408-17. PubMed ID: 36879424 [TBL] [Abstract][Full Text] [Related]
2. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Schwartz GG; Gabriel Steg P; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Manvelian G; Pordy R; Sourdille T; White HD; Szarek M; Circulation; 2021 Mar; 143(11):1109-1122. PubMed ID: 33438437 [TBL] [Abstract][Full Text] [Related]